Close
| Sponsor | PTC therapeutics |
| CI | Professor Kate Bushby |
| sites | Newcastle and London GOSH |
| Contact |
Newcastle: becky.davis@ncl.ac.uk London: c.uzowuru@ucl.ac.uk |
| More information on the trial |
|
Primary Objective
To assess the long-term safety of Ataluren in boys with nonsense mutation dystrophinopathy. This will be determined by adverse events and laboratory abnormalities.
All patients who completed PTC20 trial will be
eligible to enter the extension.